Xin Yue1, Carla L Black2, Alissa O'Halloran3, Peng-Jun Lu2, Walter W Williams2, Noele P Nelson4. 1. Leidos Inc., Atlanta, GA, United States. Electronic address: hwg3@cdc.gov. 2. Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. 3. Leidos Inc., Atlanta, GA, United States. 4. Division of Viral Hepatitis, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Abstract
BACKGROUND: Infection with hepatitis A and hepatitis B virus can increase the risk of morbidity and mortality in persons with chronic liver disease (CLD). The Advisory Committee on Immunization Practices recommends hepatitis A (HepA) and hepatitis B (HepB) vaccination for persons with CLD. METHODS: Data from the 2014 and 2015 National Health Interview Surveys (NHIS), nationally representative, in-person interview surveys of the non-institutionalized US civilian population, were used to assess self-reported HepA (≥1 and ≥2 doses) and HepB vaccination (≥1 and ≥3 doses) coverage among adults who reported a chronic or long-term liver condition. Multivariable logistic regression was used to identify factors independently associated with HepA and HepB vaccination among adults with CLD. RESULTS: Overall, 19.4% and 11.5% of adults aged ≥ 18 years with CLD reported receiving ≥1 dose and ≥2 doses of HepA vaccine, respectively, compared with 14.7% and 9.1% of adults without CLD (p < .05 comparing those with and without CLD, ≥1dose). Age, education, geographic region, and international travel were associated with receipt of ≥2 doses HepA vaccine among adults with CLD. Overall, 35.7% and 29.1% of adults with CLD reported receiving ≥1 dose and ≥3 doses of HepB vaccine, respectively, compared with 30.2% and 24.7% of adults without CLD (p < .05 comparing those with and without CLD, ≥1 dose). Age, education, and receipt of influenza vaccination in the past 12 months were associated with receipt of ≥3 doses HepB vaccine among adults with CLD. Among adults with CLD and ≥10 provider visits, only 13.8% and 35.3% had received ≥2 doses HepA and ≥3 doses HepB vaccine, respectively. CONCLUSIONS: HepA and HepB vaccination among adults with CLD is suboptimal and missed opportunities to vaccinate occurred. Providers should adhere to recommendations to vaccinate persons with CLD to increase vaccination among this population.
BACKGROUND: Infection with hepatitis A and hepatitis B virus can increase the risk of morbidity and mortality in persons with chronic liver disease (CLD). The Advisory Committee on Immunization Practices recommends hepatitis A (HepA) and hepatitis B (HepB) vaccination for persons with CLD. METHODS: Data from the 2014 and 2015 National Health Interview Surveys (NHIS), nationally representative, in-person interview surveys of the non-institutionalized US civilian population, were used to assess self-reported HepA (≥1 and ≥2 doses) and HepB vaccination (≥1 and ≥3 doses) coverage among adults who reported a chronic or long-term liver condition. Multivariable logistic regression was used to identify factors independently associated with HepA and HepB vaccination among adults with CLD. RESULTS: Overall, 19.4% and 11.5% of adults aged ≥ 18 years with CLD reported receiving ≥1 dose and ≥2 doses of HepA vaccine, respectively, compared with 14.7% and 9.1% of adults without CLD (p < .05 comparing those with and without CLD, ≥1dose). Age, education, geographic region, and international travel were associated with receipt of ≥2 doses HepA vaccine among adults with CLD. Overall, 35.7% and 29.1% of adults with CLD reported receiving ≥1 dose and ≥3 doses of HepB vaccine, respectively, compared with 30.2% and 24.7% of adults without CLD (p < .05 comparing those with and without CLD, ≥1 dose). Age, education, and receipt of influenza vaccination in the past 12 months were associated with receipt of ≥3 doses HepB vaccine among adults with CLD. Among adults with CLD and ≥10 provider visits, only 13.8% and 35.3% had received ≥2 doses HepA and ≥3 doses HepB vaccine, respectively. CONCLUSIONS:HepA and HepB vaccination among adults with CLD is suboptimal and missed opportunities to vaccinate occurred. Providers should adhere to recommendations to vaccinate persons with CLD to increase vaccination among this population.
Authors: Eric E Mast; Cindy M Weinbaum; Anthony E Fiore; Miriam J Alter; Beth P Bell; Lyn Finelli; Lance E Rodewald; John M Douglas; Robert S Janssen; John W Ward Journal: MMWR Recomm Rep Date: 2006-12-08
Authors: Carolyn B Bridges; Laura P Hurley; Walter W Williams; Aparna Ramakrishnan; Anna K Dean; Amy V Groom Journal: Vaccine Date: 2015-11-27 Impact factor: 3.641
Authors: Sven Breitschwerdt; Carolynne Schwarze-Zander; Ahmad Al Tayy; Julia Mutevelli; Jan-Christian Wasmuth; Jürgen K Rockstroh; Christoph Boesecke Journal: Infection Date: 2022-05-06 Impact factor: 7.455
Authors: Joyce LaMori; Xue Feng; Christopher D Pericone; Marco Mesa-Frias; Obiageli Sogbetun; Andrzej Kulczycki Journal: PLoS One Date: 2022-02-17 Impact factor: 3.240
Authors: Caterina De Sarro; Rosa Papadopoli; Maria Carmela Morgante; Carmelo Giuseppe Angelo Nobile; Giovambattista De Sarro; Claudia Pileggi Journal: Vaccines (Basel) Date: 2022-08-14